PE20151808A1 - Peptidos terapeuticos - Google Patents
Peptidos terapeuticosInfo
- Publication number
- PE20151808A1 PE20151808A1 PE2015002329A PE2015002329A PE20151808A1 PE 20151808 A1 PE20151808 A1 PE 20151808A1 PE 2015002329 A PE2015002329 A PE 2015002329A PE 2015002329 A PE2015002329 A PE 2015002329A PE 20151808 A1 PE20151808 A1 PE 20151808A1
- Authority
- PE
- Peru
- Prior art keywords
- pyy
- analogs
- therapeutic peptides
- diet
- lean
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 abstract 3
- 108010088847 Peptide YY Proteins 0.000 abstract 2
- 102100029909 Peptide YY Human genes 0.000 abstract 2
- 101000585528 Homo sapiens Peptide YY Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000011643 diet-induced obesity animal model Methods 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se refiere a analogos novedosos del peptido YY (PYY) que tienen un perfil terapeutico mejorado cuando se comparan con PYY nativo de humano. Estos analogos de PYY son utiles en el tratamiento de obesidad, diabetes y otros trastornos metabolicos. De manera preferida, los polipeptidos reducen la ingesta de alimentos en un modelo animal magro y/o de obesidad inducida por dieta en por lo menos 50%
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818624P | 2013-05-02 | 2013-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151808A1 true PE20151808A1 (es) | 2015-12-16 |
Family
ID=50842285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002329A PE20151808A1 (es) | 2013-05-02 | 2014-04-30 | Peptidos terapeuticos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20160108098A1 (es) |
| EP (1) | EP2992008B1 (es) |
| JP (1) | JP2016519130A (es) |
| KR (1) | KR20160003848A (es) |
| CN (1) | CN105263957A (es) |
| AR (1) | AR096162A1 (es) |
| AU (1) | AU2014261111B2 (es) |
| BR (1) | BR112015027528B1 (es) |
| CA (1) | CA2909045C (es) |
| CL (1) | CL2015003199A1 (es) |
| EA (1) | EA201591839A1 (es) |
| ES (1) | ES2732291T3 (es) |
| HK (1) | HK1214829A1 (es) |
| MX (1) | MX2015015249A (es) |
| PE (1) | PE20151808A1 (es) |
| RU (1) | RU2015144632A (es) |
| SG (1) | SG11201508469YA (es) |
| TW (1) | TW201534616A (es) |
| UY (1) | UY35548A (es) |
| WO (1) | WO2014178018A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| CA2909045C (en) * | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| US9085637B2 (en) * | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| WO2016124687A1 (en) * | 2015-02-04 | 2016-08-11 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| US10808253B2 (en) | 2015-12-28 | 2020-10-20 | Idemitsu Kosan Co., Ltd. | Peptide tag and tagged protein including same |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| US20200188479A1 (en) | 2017-03-08 | 2020-06-18 | Intarcia Therapeutics, Inc. | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| US10875902B2 (en) | 2018-04-25 | 2020-12-29 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
| TW202535916A (zh) * | 2018-11-01 | 2025-09-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| CA3163507A1 (en) * | 2019-12-04 | 2021-06-10 | The Scripps Research Institute | Peptide conjugates and methods of use |
| MX2022013024A (es) * | 2020-04-17 | 2023-03-15 | I2O Therapeutics Inc | Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos. |
| WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| JP2025526148A (ja) | 2022-08-18 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療 |
| CN115960258B (zh) * | 2022-09-30 | 2024-01-12 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
| WO2025217640A1 (en) * | 2024-04-12 | 2025-10-16 | Eli Lilly And Company | Compositions and methods for treating metabolic diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| JP2001501593A (ja) | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 胃腸運動を調節するための方法 |
| CA2299425A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
| PT1032587E (pt) | 1997-11-14 | 2008-04-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
| CA2320371C (en) | 1998-02-13 | 2012-01-17 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| WO2002013786A2 (en) | 2000-08-15 | 2002-02-21 | Board Of Trustees Of The University Of Illinois | Method of forming microparticles |
| NZ532427A (en) * | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US8603969B2 (en) * | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| CA2577821A1 (en) * | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
| EP2360180A3 (en) | 2004-12-13 | 2012-02-08 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CN101405020A (zh) * | 2006-03-23 | 2009-04-08 | 安米林药品公司 | 代谢疾病治疗中的内皮素和内皮素受体激动剂 |
| BR112012007374A2 (pt) | 2009-09-30 | 2019-09-24 | Glaxo Group Ltd | composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante |
| WO2011050008A2 (en) * | 2009-10-19 | 2011-04-28 | Amylin Pharmaceuticals, Inc. | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| EP2600887A4 (en) * | 2010-07-09 | 2014-01-22 | Amylin Pharmaceuticals Llc | MICROCRYSTALLINE Y RECEPTOR AGONISTS |
| GB201101459D0 (en) * | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| CA2909045C (en) * | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| US9085637B2 (en) * | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
-
2014
- 2014-04-30 CA CA2909045A patent/CA2909045C/en active Active
- 2014-04-30 UY UY0001035548A patent/UY35548A/es not_active Application Discontinuation
- 2014-04-30 RU RU2015144632A patent/RU2015144632A/ru not_active Application Discontinuation
- 2014-04-30 AR ARP140101793A patent/AR096162A1/es unknown
- 2014-04-30 EA EA201591839A patent/EA201591839A1/ru unknown
- 2014-04-30 ES ES14727241T patent/ES2732291T3/es active Active
- 2014-04-30 KR KR1020157034300A patent/KR20160003848A/ko not_active Ceased
- 2014-04-30 MX MX2015015249A patent/MX2015015249A/es unknown
- 2014-04-30 SG SG11201508469YA patent/SG11201508469YA/en unknown
- 2014-04-30 TW TW103115659A patent/TW201534616A/zh unknown
- 2014-04-30 JP JP2016511159A patent/JP2016519130A/ja active Pending
- 2014-04-30 CN CN201480024836.3A patent/CN105263957A/zh active Pending
- 2014-04-30 PE PE2015002329A patent/PE20151808A1/es not_active Application Discontinuation
- 2014-04-30 EP EP14727241.3A patent/EP2992008B1/en active Active
- 2014-04-30 US US14/888,085 patent/US20160108098A1/en not_active Abandoned
- 2014-04-30 BR BR112015027528-1A patent/BR112015027528B1/pt active IP Right Grant
- 2014-04-30 AU AU2014261111A patent/AU2014261111B2/en active Active
- 2014-04-30 WO PCT/IB2014/061123 patent/WO2014178018A1/en not_active Ceased
- 2014-04-30 HK HK16102709.0A patent/HK1214829A1/zh unknown
- 2014-04-30 US US14/265,831 patent/US9441023B2/en active Active
-
2015
- 2015-10-30 CL CL2015003199A patent/CL2015003199A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160108098A1 (en) | 2016-04-21 |
| CA2909045A1 (en) | 2014-11-06 |
| HK1214829A1 (zh) | 2016-08-05 |
| MX2015015249A (es) | 2016-02-09 |
| TW201534616A (zh) | 2015-09-16 |
| CA2909045C (en) | 2022-12-06 |
| UY35548A (es) | 2014-11-28 |
| AU2014261111B2 (en) | 2017-03-16 |
| US9441023B2 (en) | 2016-09-13 |
| EP2992008B1 (en) | 2019-04-10 |
| EA201591839A1 (ru) | 2016-05-31 |
| KR20160003848A (ko) | 2016-01-11 |
| BR112015027528A2 (pt) | 2017-12-05 |
| AU2014261111A1 (en) | 2015-11-19 |
| RU2015144632A (ru) | 2017-06-07 |
| US20140329742A1 (en) | 2014-11-06 |
| EP2992008A1 (en) | 2016-03-09 |
| ES2732291T3 (es) | 2019-11-21 |
| WO2014178018A1 (en) | 2014-11-06 |
| JP2016519130A (ja) | 2016-06-30 |
| CN105263957A (zh) | 2016-01-20 |
| CL2015003199A1 (es) | 2016-05-06 |
| SG11201508469YA (en) | 2015-11-27 |
| AR096162A1 (es) | 2015-12-09 |
| BR112015027528B1 (pt) | 2023-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151808A1 (es) | Peptidos terapeuticos | |
| SV2017005594A (es) | Compuestos co-agonistas de glucagon y glp-1 | |
| MX2018014016A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
| CY1122539T1 (el) | Αναλογα γλυκαγονης | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| ECSP19046893A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| CO7400885A2 (es) | Análogos de glucagón | |
| BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| GT201400055A (es) | Proteínas de fusión para tratar trastornos metabolicos | |
| UY33739A (es) | Metodos de tratamiento de trastornos asociados con el fgf21 | |
| UY34859A (es) | Análogos peptídicos de la exendina 4. | |
| MX2016006049A (es) | Mimeticos de calcitonina para tratar enfermedades y trastornos. | |
| MX2019003710A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
| BR112018010155A8 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
| EA201992562A1 (ru) | Пептиды для лечения сахарного диабета | |
| EA201890163A1 (ru) | Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью | |
| PL3648788T3 (pl) | Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf | |
| BR112015017909A2 (pt) | redução do risco de doença autoimune | |
| CY1120861T1 (el) | Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1 | |
| PT3648787T (pt) | Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante | |
| ECSP15009978A (es) | Análogos de glucagón |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |